A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Invest New Drugs
; 38(4): 1145-1155, 2020 08.
Article
in En
| MEDLINE
| ID: mdl-31707688
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrazines
/
Pyrazoles
/
Pyridines
/
Antineoplastic Combined Chemotherapy Protocols
/
P38 Mitogen-Activated Protein Kinases
/
Protein Kinase Inhibitors
/
Checkpoint Kinase 1
/
Imidazoles
/
Neoplasms
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Invest New Drugs
Year:
2020
Type:
Article
Affiliation country:
United States